PAP Therapy Reduces Hospitalizations by 31% and ER Visits by 23% for People with Obstructive Sleep Apnea and Comorbid Insomnia
ResMed presented 13 new clinical studies at SLEEP 2024, highlighting the effectiveness of PAP therapy for Obstructive Sleep Apnea (OSA) and comorbid insomnia (COMISA). Key findings include a 31% reduction in hospitalizations and a 23% decrease in ER visits among COMISA patients adhering to PAP therapy. The research also revealed a 17% prevalence of insomnia in adults across North America, Latin America, and the Caribbean, and higher rates of depression in women with OSA. The studies underscore the importance of sleep health and PAP therapy in improving patient outcomes.
- PAP therapy reduces hospitalizations by 31% for COMISA patients.
- ER visits decrease by 23% with PAP therapy adherence.
- 17% prevalence of insomnia among adults in North America, Latin America, and the Caribbean highlights the need for better sleep health initiatives.
- Research emphasizes the effectiveness of PAP therapy for OSA.
- Clinical studies presented at a major event, SLEEP 2024, enhancing ResMed's credibility.
- 25.5% of women with OSA and depression show lower adherence to PAP therapy.
- Individuals with OSA and depression have a higher burden of severe obesity, hypertension, type 2 diabetes, coronary artery disease, and heart failure.
- Higher rates of depression in women with OSA may indicate a need for more targeted interventions.
Insights
The studies presented by ResMed place significant emphasis on the clinical efficacy of PAP therapy for patients with Obstructive Sleep Apnea (OSA) and comorbid insomnia (COMISA). The reduction in hospitalizations by 31% and ER visits by 23% among those adhering to PAP therapy showcases a tangible benefit in terms of healthcare utilization. This is notable given the rising costs associated with hospital stays and emergency visits. Furthermore, the finding that 17% of adults in the Americas have insomnia underlines a significant public health concern, urging health systems to prioritize sleep health initiatives. From a clinical perspective, these data suggest that investing in PAP therapy and related sleep health programs could yield substantial health improvements and cost savings.
For investors, ResMed's presentation at SLEEP 2024 provides useful insights into the potential economic impact of their products. The significant reduction in hospitalizations and ER visits for patients adhering to PAP therapy not only highlights the effectiveness of ResMed's product but also suggests a potential for increased market adoption. The prevalence of insomnia in the adult population across the Americas indicates a broad market for ResMed's solutions. Moreover, addressing gender-specific issues in OSA and depression suggests that ResMed is targeting specific sub-segments of the market, which could lead to a diversification of their customer base. Financially, these findings might translate into higher sales and a solid long-term growth trajectory for the company.
The revelations from SLEEP 2024 shed light on the growing market potential for sleep health products. The identification of a 17% prevalence of insomnia and its impact on health and hospital admissions underscores a significant demand for effective sleep solutions. ResMed's focus on real-world evidence and demographic-specific studies, such as the higher depression rates among women with OSA, positions them as a forward-thinking leader in the sleep health industry. This indicates opportunities for market penetration, particularly in regions highlighted by the studies. As healthcare providers and insurance companies look for cost-effective treatments, ResMed's data-driven approach could set a new industry standard, potentially increasing their market share and brand loyalty.
ResMed studies presented at SLEEP 2024 also revealed a
SAN DIEGO, June 10, 2024 (GLOBE NEWSWIRE) -- In collaboration with leading medical researchers from around the world, ResMed (NYSE: RMD, ASX: RMD) presented 13 new clinical studies at SLEEP 2024, the annual joint meeting of the American Academy of Sleep Medicine and the Sleep Research Society. Held in Houston, the event brought together scientific and medical experts focused on sleep health. From exploration into the prevalence of insomnia in the Americas to the reduction in emergency room visits among COMISA patients on PAP therapy – the ResMed-supported research demonstrated the effectiveness and value of positive airway pressure (PAP) treatment for OSA.
“The real-world evidence used in our clinical research continues to demonstrate the effectiveness of PAP therapy for treating OSA,” said Carlos M. Nunez, MD, ResMed’s Chief Medical Officer. “The studies presented at SLEEP 2024 expand our understanding of patients with sleep disorders by examining critical areas such as the effect of demographic factors like gender on sleep health. The body of knowledge we have created and are continually expanding with research partners who are highly respected in their fields helps ResMed and the medical community achieve the goal of helping people live their healthiest lives.”
Prevalence of Insomnia among Adults in the Americas Signals the Need to Prioritize Sleep Health
A study presented by Adam Benjafield, PhD, vice president of clinical research at ResMed, examined the prevalence of insomnia across Northern America, Latin America, and the Caribbean. Reviewing studies and survey data across 55 countries, the researchers extrapolated that approximately
Adherence to PAP Therapy Linked to Fewer Hospital Visits Among Patients with OSA and Comorbid Insomnia
Atul Malhotra, MD, Director of Research for Pulmonary, Critical Care and Sleep Medicine at the University of California, San Diego, presented results of a study looking at the clinical and economic impact of treating OSA with PAP therapy among patients with OSA and comorbid insomnia, a combination known as COMISA. Using administrative claims data, the researchers found that all-cause hospitalizations and emergency room visits for these patients were lower among those who consistently adhered to PAP therapy when compared to those who demonstrated lower PAP adherence (all-cause hospitalizations per person 0.09 vs 0.13, p<0.001; emergency room visits per person 0.46 vs 0.60, p<0.001). The study concluded that PAP therapy, when adhered to, can improve health outcomes among patients with COMISA.
Women With OSA More Likely to Suffer from Depression and Fall Off PAP Therapy
Aimed at understanding the relationship between OSA and depression, ResMed’s clinical researchers and Sanjay Patel, MD, Medical Director, UPMC Comprehensive Sleep Disorders Program, analyzed more than 345K adults with OSA who had begun PAP therapy from administrative claims data. Of the nearly
About ResMed
At ResMed (NYSE: RMD, ASX: RMD) we pioneer innovative solutions that treat and keep people out of the hospital, empowering them to live healthier, higher-quality lives. Our digital health technologies and cloud-connected medical devices transform care for people with sleep apnea, COPD, and other chronic diseases. Our comprehensive out-of-hospital software platforms support the professionals and caregivers who help people stay healthy in the home or care setting of their choice. By enabling better care, we improve quality of life, reduce the impact of chronic disease, and lower costs for consumers and healthcare systems in more than 140 countries. To learn more, visit ResMed.com and follow @ResMed.
| For Media | For Investors | |
| Peter Duckler | Mike Ott | |
| pduckler@realchemistry.com | investorrelations@resmed.com | |
| Rowena Kelley | ||
| news@resmed.com |
FAQ
How effective is PAP therapy for reducing hospitalizations in COMISA patients?
What impact does PAP therapy have on emergency room visits for COMISA patients?
What is the prevalence of insomnia among adults in North America, Latin America, and the Caribbean?
Are women with OSA more likely to suffer from depression?
What additional health burdens do individuals with OSA and depression face?
